Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer

British Journal of Cancer

Volumn 73, Issue 10, 1996, Pages 1265-1267

  Planting, A S T ^a   Van Der Burg, M E L ^a   Van Den Bent, M J ^a   De Boer Dennert, M ^a   Stoter, G ^a   Verweij, J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Cisplatin; Colorectal cancer; Oral etoposide; Phase II study

Indexed keywords

ANTINEOPLASTIC ALKALOID; ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; ETOPOSIDE;

ADULT; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TINNITUS; VOMITING;

EID: 0029896893     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.242     Document Type: Article

References (17)

1. DESIMONE PA, DAVILA E, JOCHIMSEN PR AND BARTOLUCCI AA. (1986). High-dose cisplatin in the treatment of advanced adenocarcinoma of the colon and rectum: a Southeastern Cancer Study Group trial. Cancer Treat. Rep., 70, 1229-1230.
2. DOUGLASS HO, LAVIN PT, EVANS JT, MITTELMAN A AND CARBONE PP. (1979). Phase II evaluation of Diglycoaldehyde, VP-16-213, and the combination of Methyl-CCNU and β-2-deoxythioguanosine in previously treated patients with colorectal cancer: An Eastern Cooperative Oncology Group Study (EST-1275). Cancer Treat. Rep., 63, 1355-1357.
3. GRECO FA, JOHNSON DH AND HAINSWORTH JD. (1990). Chronic daily administration of oral etoposide. Semin. Oncol., 17, (suppl.1), 71-74.
4. HILKENS PHE, PLANTING AST, VAN DER BURG MEL, MOLL JWB, VAN PUTTEN WLJ, VECHT CHJ AND VAN DEN BENT MJ. (1994). Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule. Eur. J. Neurol., 1, 45-50.
5. KEMENY N, ISRAEL K, NIEDZWIECKI D, CHAPMAN D, BOTET J, MINSKY B, VINCIGU-ERRA V, ROSENBLUTH R, BOSSELLI B, COCHRAN C AND SHEEHAN K. (1990). Randomised study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J. Clin. Oncol., 8, 313-318.
6. LABIANCA R, PANCERA G, CESANA B, CLERICI M, MONTINARI F AND LUPORINI G. (1988). Cisplatin + 5-Fluorouracil versus 5-Fluorouracil alone in advanced colorectal cancer: randomized study. Eur. J. Cancer Clin. Oncol., 24, 1579-1581.
7. LOEHRER PJ, TURNER S, KUBILIS P, HUI S, CORREA J, ANSARI R, STEPHENS D, WOODBURN R AND MEYER S. (1988). A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: A Hoosier Oncology Group Trial. J. Clin. Oncol., 6, 642-648.
8. LOKICH JL, AHLGREN JD, CANTRELL J, HEIM WJ, WAMPLER GL, GULLO JJ, FRYER JG AND ALT DE. (1991). A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. Cancer, 67, 14-19.
9. LORUSS OP, PAZDUR R, REDMAN BG, KINZIE J AND VAITKEVICIUS V. (1989). Low-dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma. Am. J. Clin. Oncol., 12, 486-490.
10. MOERTEL CG. (1994). Chemotherapy for colorectal cancer. N. Engl. J. Med., 330, 1136-1142.
11. PASSALACQUA R, BISAGNI G, COCCONI G, BONI C, DIBLASIO B AND CECI G. (1991). Cisplatin and etoposide in advanced colorectal carcinoma. Ann. Oncol., 2, 687-688.
12. PERRY MC, MOERTEL CG, SCHUTT AJ, REITEMEIER RJ AND HAHN RG. (1976). Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer. Cancer Treat. Rep., 60, 1247-1250.
13. PLANTING AST, VAN DER BURG MEL, DE BOER-DENNERT M, STOTER G AND VERWEIJ J. (1995). Phase I study of weekly high dose cisplatin combined with long term oral etoposide in advanced solid tumours. Ann. Oncol., 6, 190-192.
14. POSNER MR, BELLIVEAU JF, WEITBERG AB, SABBATH K, WIEMANN MC, CUMMINGS FJ AND CALABRESI P. (1987). Continuous-infusion cisplatin and bolus 5-fluorouracil in colorectal carcinoma. Cancer Treat. Rep., 71, 975-977.
15. SCHEITHAUER W, DEPISCH D, KORNEK G, PIDLICH J, ROSEN H, KARALL M, PROCHASKA M, ERNST A, SEBESTA C AND ECKHARDT S. (1994). Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin and cisplatin therapy in patients with advanced colorectal cancer. Cancer, 73, 1562-1568.
16. WHO. (1979). Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No.48. World Health Organization: Geneva.
17. ZANIBONI A, LABIANCA R, PANCERA G, BARNI S, FRONTINI L, MARINI G AND LUPORINI G. (1995). Oral etoposide as second-line chemotherapy for colorectal cancer: a GISCAD study. J. Chemother., 7, 246-248.